+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics

  • ID: 5303640
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Congenica Ltd.
  • Dnastar, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genuity Science
  • Illumina, Inc.
  • PierianDx
Global Next Generation Sequencing (NGS) Data Analysis Market to Reach $1.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$638.8 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 12.2% over the period 2020-2027. Services, one of the segments analyzed in the report, is projected to record 12.5% CAGR and reach US$836.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 11.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $188.6 Million, While China is Forecast to Grow at 11.7% CAGR

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$188.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$249.7 Million by the year 2027 trailing a CAGR of 11.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Select Competitors (Total 33 Featured):
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Congenica Ltd.
  • DNAnexus Inc.
  • Dnastar, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fabric Genomics, Inc.
  • Genuity Science
  • Golden Helix, Inc.
  • Illumina, Inc.
  • Intrexon Bioinformatics Germany GmbH
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • PierianDx
  • Qiagen
  • SciGenom Labs Pvt. Ltd.
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Congenica Ltd.
  • Dnastar, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genuity Science
  • Illumina, Inc.
  • PierianDx
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 21: World Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 22: World 7-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 23: World Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 24: World 7-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 25: World Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 26: World 7-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 27: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 29: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 31: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 33: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 34: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • CANADA
  • Table 35: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 36: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 37: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 39: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 40: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 41: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 42: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • JAPAN
  • Table 43: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 45: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 46: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 47: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 48: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 49: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • CHINA
  • Table 51: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 52: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 53: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 54: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 55: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 57: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 58: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • EUROPE
  • Table 59: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 60: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 61: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 63: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 64: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 65: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 66: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 67: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • FRANCE
  • Table 69: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 70: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 71: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 72: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 73: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 75: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 76: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • GERMANY
  • Table 77: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 78: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 79: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 81: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 82: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 83: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 84: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • ITALY
  • Table 85: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 87: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 88: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 89: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 90: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 91: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • UNITED KINGDOM
  • Table 93: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 94: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 95: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 96: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 97: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 98: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 99: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 100: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • REST OF EUROPE
  • Table 101: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 102: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 103: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 104: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 105: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 106: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 107: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 108: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • ASIA-PACIFIC
  • Table 109: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 110: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 111: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 112: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 113: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 114: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 115: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 116: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
  • REST OF WORLD
  • Table 117: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 118: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027
  • Table 119: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 120: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027
  • Table 121: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 122: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027
  • Table 123: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 124: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 33
Note: Product cover images may vary from those shown
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Congenica Ltd.
  • DNAnexus Inc.
  • Dnastar, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fabric Genomics, Inc.
  • Genuity Science
  • Golden Helix, Inc.
  • Illumina, Inc.
  • Intrexon Bioinformatics Germany GmbH
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • PierianDx
  • Qiagen
  • SciGenom Labs Pvt. Ltd.
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll